Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology
Allosteric modulation
Publications
Partners & collaboration
Investors
Addex Corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
08.27
2024
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
07.22
2024
Addex’s Partner Discontinues ADX71149 development in Epilepsy
07.15
2024
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
07.12
2024
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
07.01
2024
Addex Shareholders Approve All Resolutions at Annual General Meeting
06.06
2024
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
06.05
2024
Addex Convenes Annual General Meeting 2024
05.31
2024
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
05.08
2024
Addex to Present at Bio€quity Europe 2024
04.29
2024
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Next
Back